Cisen Pharmaceutical Co Ltd (603367) — Working Capital to Net Assets Ratio
Cisen Pharmaceutical Co Ltd (603367) has a Working Capital to Net Assets ratio of 63.1% as of September 2025. Working capital of CN¥3.91 Billion (current assets of CN¥5.19 Billion minus current liabilities of CN¥1.28 Billion) is measured against net assets of CN¥6.19 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Cisen Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Cisen Pharmaceutical Co Ltd Working Capital to Net Assets (2011–2024)
This chart shows how Cisen Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 63.1%, reflecting working capital of CN¥3.91 Billion against net assets of CN¥6.19 Billion CNY. Check tangible equity quality of Cisen Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Cisen Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Cisen Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market value of Cisen Pharmaceutical Co Ltd.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 58.0% | CN¥3.47 Billion | CN¥5.99 Billion | CN¥4.96 Billion | CN¥1.49 Billion | ▼ -4.4 pp |
| 2023 | 62.4% | CN¥3.60 Billion | CN¥5.77 Billion | CN¥4.97 Billion | CN¥1.37 Billion | ▼ -2.2 pp |
| 2022 | 64.7% | CN¥3.46 Billion | CN¥5.36 Billion | CN¥4.74 Billion | CN¥1.28 Billion | ▲ +6.8 pp |
| 2021 | 57.9% | CN¥2.93 Billion | CN¥5.06 Billion | CN¥4.14 Billion | CN¥1.22 Billion | ▲ +2.4 pp |
| 2020 | 55.5% | CN¥2.67 Billion | CN¥4.80 Billion | CN¥3.95 Billion | CN¥1.28 Billion | ▼ -7.8 pp |
| 2019 | 63.3% | CN¥2.90 Billion | CN¥4.57 Billion | CN¥3.78 Billion | CN¥885.54 Million | ▲ +1.1 pp |
| 2018 | 62.3% | CN¥2.59 Billion | CN¥4.15 Billion | CN¥3.60 Billion | CN¥1.01 Billion | ▲ +4.1 pp |
| 2017 | 58.2% | CN¥2.17 Billion | CN¥3.72 Billion | CN¥3.09 Billion | CN¥918.88 Million | ▲ +25.0 pp |
| 2016 | 33.1% | CN¥761.57 Million | CN¥2.30 Billion | CN¥1.50 Billion | CN¥735.54 Million | ▲ +18.2 pp |
| 2015 | 14.9% | CN¥313.16 Million | CN¥2.10 Billion | CN¥1.16 Billion | CN¥851.02 Million | ▲ +9.5 pp |
| 2014 | 5.4% | CN¥103.37 Million | CN¥1.90 Billion | CN¥806.45 Million | CN¥703.07 Million | ▼ -11.8 pp |
| 2013 | 17.3% | CN¥297.96 Million | CN¥1.73 Billion | CN¥856.77 Million | CN¥558.81 Million | ▼ -17.8 pp |
| 2012 | 35.1% | CN¥555.61 Million | CN¥1.58 Billion | CN¥1.01 Billion | CN¥452.88 Million | ▼ -6.0 pp |
| 2011 | 41.0% | CN¥551.42 Million | CN¥1.34 Billion | CN¥777.44 Million | CN¥226.02 Million | — |